Patients featured are compensated by ViiV Healthcare.
What do the studies say?
If you are considering switching treatment or are new to treatment, DOVATO is clinically proven to be as effective as a regimen containing 3 or 4 medicines. See details below.
DOVATO WAS PROVEN TO HELP PEOPLE ALREADY ON TREATMENT STAY UNDETECTABLE
as effectively as an HIV regimen containing 3 or 4 medicines*
Less than 1% had a detectable viral load (50 or more copies per mL) with DOVATO or a 3- or 4-drug regimen* at about 1 year
Similar results were seen at about 3 years.
Through ~3 years of this study, no patients who switched to DOVATO developed HIV resistance
Results showed that DOVATO works as well as a 3- or 4-drug regimen in diverse groups of adults, regardless of age, sex, race, or CD4 T-cell count.
Side Effects
In this study, 15% of patients taking DOVATO versus 5% taking a 3- or 4-drug regimen* experienced side effects over ~3 years. The majority of side effects were mild in severity.
The most common side effects were:
-
Taking DOVATO: weight gain (3%), trouble sleeping (2%), nausea (1%), diarrhea (1%), and anxiety (1%).
- Taking a 3- or 4-drug regimen*: weight gain (2%), nausea (<1%), diarrhea (<1%), and anxiety (<1%).
*Tenofovir alafenamide (TAF)–containing 3- or 4-drug regimen.
PROVEN EFFECTIVE IN PEOPLE NEW TO HIV TREATMENT
In two combined studies, DOVATO was proven to help people new to treatment reach and stay undetectable (less than 50 copies per mL) as effectively as a regimen containing 3 medicines.†
The majority of people who took DOVATO reached and remained undetectable over ~3 years
Side Effects
Across the two combined studies, 20% of patients taking DOVATO versus 27% taking a 3-drug regimen† experienced side effects over ~3 years.
The most common side effects were:
- Taking DOVATO: headache (3%), nausea (2%), diarrhea (2%), trouble sleeping (2%), tiredness (2%), anxiety (2%), and dizziness (1%).
- Taking a 3-drug regimen†: headache (4%), nausea (6%), diarrhea (3%), trouble sleeping (3%), tiredness (2%), anxiety (<1%), and dizziness (2%).
†Dolutegravir + tenofovir disoproxil fumarate/emtricitabine.
PMUS-DLLWCNT240080